Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 13 EP applications Fredrik Fredh has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 17, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11746252

ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/32
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
PATENT GRANTED
EP11781571

SILENT FC VARIANTS OF ANTI-CD40 ANTIBODIES

IPC classification:
C07K 16/28
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
PATENT GRANTED
EP12716629

MARKERS ASSOCIATED WITH CYCLIN-DEPENDENT KINASE INHIBITORS

IPC classification:
C12Q 1/68, G01N 33/50
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14708950

ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS

IPC classification:
A61K 39/395, C07K 14/54, C07K 16/24
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14723915

ANTIBODY DRUG CONJUGATES

IPC classification:
A61K 47/48, A61P 35/00, A61P 35/02, C07K 16/28
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14802531

ORGANIC COMPOUNDS

IPC classification:
G01N 33/50
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14824309

LEPTIN mRNA COMPOSITIONS AND FORMULATIONS

IPC classification:
A61K 9/00, A61K 9/14, A61K 9/51, A61K 31/00, A61K 38/00, A61K 47/48
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15759938

IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2

IPC classification:
C07K 16/24
Applicant:
University of Zurich (Universität Zürich)
Applicant:
Novartis AG
Agent:
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15766632

ANTI-CDH6 ANTIBODY DRUG CONJUGATES

IPC classification:
A61K 31/00, A61K 39/395, A61P 35/00, C07K 16/28
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15767598

INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES

IPC classification:
A61K 31/713, A61P 35/00, C12N 15/113, G01N 33/574
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
Request for examination was made
EP15798251

ANTIBODY DRUG CONJUGATES

IPC classification:
A61P 35/00, C07K 16/28, A61K 47/50
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
Request for examination was made
EP17165506

SILENT FC VARIANTS OF ANTI-CD40 ANTIBODIES

IPC classification:
C07K 16/28
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
The application has been published
EP15816534

TREATMENT OF BREAST CANCER BRAIN METASTASES

IPC classification:
A61K 31/4741, A61K 38/17, A61K 39/395, A61K 45/00
Applicant:
Novartis AG
Agent:
Fredrik Fredh, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature